Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

XGN

Exagen Inc

Feb 13 • 04:00PM ET

3.28

+0.04 1.23 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN ONC MYGN QGEN NTRA GH VCYT CDNA PRPO FLGT

| Held by: VTI VXF IWC ROSC DFAS DFAC DFSU DCOR

Index	-	P/E	-	EPS (ttm)	-0.93	Insider Own	36.09%	Shs Outstand	22.51M	Perf Week	-6.55%
Market Cap	74.33M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-0.63%	Shs Float	14.48M	Perf Month	-35.56%
Enterprise Value	66.85M	PEG	-	EPS next Q	-0.20	Inst Own	46.63%	Short Float	4.05%	Perf Quarter	-65.80%
Income	-19.04M	P/S	1.17	EPS this Y	-7.66%	Inst Trans	1.95%	Short Ratio	1.24	Perf Half Y	-64.90%
Sales	63.60M	P/B	4.07	EPS next Y	42.25%	ROA	-35.78%	Short Interest	0.59M	Perf YTD	-46.05%
Book/sh	0.81	P/C	2.08	EPS next 5Y	34.68%	ROE	-122.81%	52W High	12.23 -73.18%	Perf Year	-23.19%
Cash/sh	1.57	P/FCF	-	EPS past 3/5Y	20.95% 19.20%	ROIC	-43.97%	52W Low	2.67 22.84%	Perf 3Y	28.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.83% 6.62%	Gross Margin	59.86%	Volatility	6.93% 8.12%	Perf 5Y	-81.98%
Dividend TTM	-	EV/Sales	1.05	EPS Y/Y TTM	1.34%	Oper. Margin	-19.62%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.81	Sales Y/Y TTM	14.08%	Profit Margin	-29.94%	RSI (14)	24.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.08	EPS Q/Q	-12.16%	SMA20	-16.61%	Beta	1.90	Target Price	13.29
Payout	-	Debt/Eq	1.55	Sales Q/Q	37.87%	SMA50	-39.30%	Rel Volume	0.50	Prev Close	3.24
Employees	209	LT Debt/Eq	1.39	Earnings	Nov 04 BMO	SMA200	-58.12%	Avg Volume	472.28K	Price	3.28
IPO	Sep 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-97.58% 2.14%	Trades		Volume	235,798	Change	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-11-25	Initiated	B. Riley Securities	Buy	$15
Jul-30-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$12
Jul-23-25	Initiated	Craig Hallum	Buy	$12
Aug-05-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-15-21	Resumed	Cowen	Outperform	$26
Apr-15-21	Initiated	Canaccord Genuity	Buy	$25
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$32
Oct-08-20	Initiated	BTIG Research	Buy	$18
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight	$19 → $20
Oct-14-19	Initiated	William Blair	Outperform
Oct-14-19	Initiated	Cowen	Outperform	$17
Oct-14-19	Initiated	Cantor Fitzgerald	Overweight	$18

Show Previous Ratings

Jan-11-26 03:00PM	Exagen Inc. Announces Select Preliminary 2025 Financial Results (GlobeNewswire)
Nov-11-25 09:00AM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Nov-04-25 04:08PM	Exagen Inc (XGN) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) -8.96%
09:10AM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Q3 2025 Results (GlobeNewswire)
08:06AM	Loading…
Nov-03-25 08:06AM	What To Expect From Exagen Inc (XGN) Q3 2025 Earnings (GuruFocus.com)
Oct-23-25 09:15AM	Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence (GlobeNewswire)
Oct-21-25 04:05PM	Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Aug-12-25 10:30PM	[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-06-25 04:05PM	Exagen Inc. to Participate in Third Quarter Investor Conferences (GlobeNewswire)
Jul-29-25 09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +14.34%
08:00AM	Exagen Inc. Reports Strong Q2 2025 Results (GlobeNewswire)
Jul-28-25 09:39AM	Exagen Inc (XGN) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-24-25 09:09AM	Exagen Inc. (XGN): A Bull Case Theory (Insider Monkey)
08:45AM	Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
04:05PM	Loading…
Jul-17-25 04:05PM	Exagen Inc. Appoints Chas McKhann to Board of Directors (GlobeNewswire)
Jul-15-25 04:05PM	Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jun-23-25 09:00AM	Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics (GlobeNewswire)
May-09-25 04:05PM	Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire) -7.31%
May-08-25 08:30AM	Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire) -9.81%
May-07-25 04:05PM	Exagen Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +6.39%
May-06-25 03:03AM	Exagen Inc (XGN) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Wins Amidst ... (GuruFocus.com)
01:18AM	Q1 2025 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 04:51PM	Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume (GlobeNewswire)
May-02-25 09:36AM	Exagen Inc (XGN) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-28-25 09:00AM	Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors (GlobeNewswire) +7.09%
Apr-26-25 03:31AM	Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability (Seeking Alpha)
Apr-21-25 04:05PM	Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +9.26%
03:04AM	Loading…
Mar-12-25 03:04AM	Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives (GuruFocus.com)
12:10AM	Q4 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 09:15AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +18.25%
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-25-25 04:05PM	Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Feb-05-25 06:38AM	Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength? (Zacks) +6.18%
Feb-04-25 04:05PM	Exagen Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire) +29.38%
Jan-12-25 12:00PM	Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results (GlobeNewswire)
Dec-12-24 09:00AM	Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD (GlobeNewswire) +12.02%
Nov-14-24 04:30PM	Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform (GlobeNewswire) +5.45%
Nov-13-24 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
02:09AM	Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com)
12:51AM	Q3 2024 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 09:25AM	Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.06%
Nov-11-24 07:25AM	Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:05PM	Exagen to Announce Third Quarter 2024 Results on November 12, 2024 (GlobeNewswire)
Oct-21-24 04:05PM	Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence (GlobeNewswire)
Sep-04-24 04:05PM	Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire) +15.93%
Aug-29-24 09:55AM	Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now (Zacks)
Aug-26-24 08:50AM	Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-09-24 09:15AM	Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? (Zacks) +22.46%
Aug-08-24 08:50AM	Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain (Zacks) +12.65%
Aug-05-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +17.65%
09:10AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance (GlobeNewswire)
Aug-02-24 09:00AM	Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 09:00AM	Exagen Appoints Jeffrey G. Black as New Chief Financial Officer (GlobeNewswire)
Jul-22-24 09:00AM	Exagen to Announce Second Quarter 2024 Results on August 5, 2024 (GlobeNewswire)
Jun-13-24 08:50AM	Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors (Zacks)
May-15-24 05:01AM	Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ... (GuruFocus.com) +8.52%
May-13-24 12:53PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:10AM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year (GlobeNewswire)
May-06-24 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -6.52%
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire) +16.44%
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75% +6.08%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)
Sep-12-23 04:05PM	Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-09-23 10:47AM	Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript (Insider Monkey) -7.22%
Aug-08-23 04:13AM	Q2 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 09:15AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.76%
08:00AM	Exagen Inc. Reports Strong Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 04:05PM	Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire) -6.51%
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
07:33AM	This Exagen Insider Increased Their Holding In The Last Year (Simply Wall St.)
Jun-13-23 08:19AM	Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement (Simply Wall St.) -8.36%
May-30-23 09:00AM	Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
May-17-23 07:11AM	Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years (Simply Wall St.) -6.90%
May-16-23 11:03AM	Q1 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents) +19.51%
May-15-23 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-01-23 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-24-23 04:05PM	Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Mar-24-23 08:16AM	Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 06:12AM	Exagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ABALLI JOHN	President and CEO	Oct 16 '25	Sale	11.82	31,787	375,598	714,427	Oct 20 05:20 PM
Black Jeffrey G.	Chief Financial Officer	Sep 02 '25	Sale	9.79	20,466	200,362	269,026	Sep 04 07:40 PM
NMSIC Co-Investment Fund, L.P.	10% Owner	Mar 25 '25	Sale	3.30	350,000	1,155,000	1,758,958	Mar 27 04:15 PM

Open in Screener

LAB

Standard BioTools Inc

Feb 13 • 04:00PM ET

1.12

+0.01 0.90 %

Healthcare • Medical Devices • USA • NASD

LAB Standard BioTools Inc daily Stock Chart

Peers: TMO DHR A ILMN BIO QGEN TECH TWST PACB DNA

| Held by: VTI IWM VXF ARKG IBB IWN VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	4.15%	Shs Outstand	383.61M	Perf Week	-11.11%
Market Cap	430.71M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	390.86%	Shs Float	368.61M	Perf Month	-29.56%
Enterprise Value	263.20M	PEG	-	EPS next Q	-0.05	Inst Own	75.89%	Short Float	2.66%	Perf Quarter	-5.08%
Income	-128.25M	P/S	3.34	EPS this Y	60.16%	Inst Trans	-1.56%	Short Ratio	5.84	Perf Half Y	-8.20%
Sales	128.83M	P/B	1.08	EPS next Y	42.98%	ROA	-17.93%	Short Interest	9.79M	Perf YTD	-12.50%
Book/sh	1.04	P/C	2.21	EPS next 5Y	42.89%	ROE	-24.63%	52W High	1.72 -34.88%	Perf Year	-15.79%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	12.51% 11.61%	ROIC	-30.40%	52W Low	0.92 21.74%	Perf 3Y	-46.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.13% 8.27%	Gross Margin	46.52%	Volatility	5.82% 6.07%	Perf 5Y	-79.82%
Dividend TTM	-	EV/Sales	2.04	EPS Y/Y TTM	52.28%	Oper. Margin	-83.21%	ATR (14)	0.08	Perf 10Y	-80.79%
Dividend Ex-Date	-	Quick Ratio	4.14	Sales Y/Y TTM	-17.37%	Profit Margin	-99.55%	RSI (14)	29.00	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	4.38	EPS Q/Q	-24.97%	SMA20	-18.78%	Beta	1.37	Target Price	1.55
Payout	-	Debt/Eq	0.07	Sales Q/Q	-56.52%	SMA50	-21.56%	Rel Volume	0.89	Prev Close	1.11
Employees	818	LT Debt/Eq	0.06	Earnings	Feb 24 AMC	SMA200	-13.07%	Avg Volume	1.68M	Price	1.12
IPO	Feb 10, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-107.85% 8.62%	Trades		Volume	1,499,376	Change	0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Downgrade	TD Cowen	Buy → Hold	$1.55
Feb-27-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Feb-10-26 07:00AM	Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-30-26 09:09AM	Standard BioTools Completes Sale of SomaLogic to Illumina (GlobeNewswire)
Jan-08-26 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue (GlobeNewswire) +20.31%
Nov-19-25 11:30AM	Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry (Business Wire)
Nov-10-25 12:15PM	Illumina Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks (PR Newswire)
05:31PM	Loading…
Nov-04-25 05:31PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 08:01AM	Earnings To Watch: Standard BioTools Inc (LAB) Reports Q3 2025 Result (GuruFocus.com)
Oct-21-25 07:00AM	Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 (GlobeNewswire)
Sep-03-25 09:15AM	Illumina Protein Prep launches to drive greater proteomic insights for improved drug discovery and development (PR Newswire)
Aug-11-25 07:00PM	Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:09PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:25AM	What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 05:30PM	Doximity (DOCS) Q1 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Loading…
Aug-06-25 07:00AM	Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study (GlobeNewswire)
Jul-21-25 07:00AM	Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 (GlobeNewswire)
Jun-26-25 08:07AM	Illumina Stock May Benefit From New Agreement to Acquire SomaLogic (Zacks)
Jun-25-25 12:16AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire)
Jun-23-25 07:13AM	Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy (PR Newswire) +17.14%
07:05AM	Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina (GlobeNewswire)
06:58AM	Illumina to buy SomaLogic for up to $425M (MedTech Dive)
May-30-25 07:00AM	Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series (GlobeNewswire)
May-09-25 05:00PM	Labrador Gold Announces Resignation of Director Kai Hoffmann (GlobeNewswire) +8.41%
May-07-25 08:26AM	Q1 2025 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
03:20AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.83%
04:01PM	Standard BioTools Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 10:10AM	Standard BioTools Inc (LAB) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 07:00AM	Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 (GlobeNewswire)
04:05PM	Loading…
Apr-22-25 04:05PM	Sight Sciences Appoints Gary Burbach to its Board of Directors (GlobeNewswire) +6.72%
07:00AM	Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 (GlobeNewswire)
Feb-27-25 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.68%
07:09AM	Q4 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
02:22AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Feb-26-25 06:52PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance) -7.14%
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 10:54AM	Standard BioTools Inc (LAB) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) -5.26%
Feb-12-25 07:00AM	Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 (GlobeNewswire)
Jan-13-25 07:00AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue (GlobeNewswire) +26.38%
Jan-08-25 07:00AM	Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine (GlobeNewswire)
Dec-19-24 08:00AM	Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 08:00AM	Standard BioTools Appoints Alex Kim as Chief Financial Officer (GlobeNewswire)
Oct-31-24 11:00AM	Standard BioTools Inc (LAB) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with ... (GuruFocus.com)
08:01AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 05:20PM	Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.43%
04:15PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-21-24 09:03PM	Millennium Management LLC Acquires Shares in Standard BioTools Inc (GuruFocus.com)
Oct-16-24 08:00AM	Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 (GlobeNewswire)
Oct-03-24 04:56AM	Is Standard BioTools Inc. (LAB) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-24-24 08:00AM	Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan 11K Platform (GlobeNewswire) +5.35%
Sep-18-24 08:00AM	Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) (GlobeNewswire)
Aug-26-24 08:00AM	Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-23-24 06:03PM	Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors (Barrons.com) +9.74%
Aug-06-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 09:14AM	Q2 2024 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -36.61%
Jul-31-24 09:57PM	LAB Stock Earnings: Standard BioTools Reported Results for Q2 2024 (InvestorPlace)
05:40PM	Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	Standard BioTools Announces Senior Leadership Changes (GlobeNewswire)
04:01PM	Standard BioTools Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:01AM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire)
May-28-24 04:01PM	Standard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers (GlobeNewswire)
May-22-24 04:01PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-24 08:00AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49% +7.59%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Partners Master Fund, L	Director	Dec 04 '25	Buy	1.45	150,000	217,020	72,100,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 02 '25	Buy	1.42	125,000	177,512	71,875,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Dec 03 '25	Buy	1.44	75,000	108,037	71,950,000	Dec 04 08:59 PM
Casdin Partners Master Fund, L	Director	Nov 25 '25	Buy	1.30	7,550,000	9,838,405	71,750,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 24 '25	Buy	1.43	150,000	214,875	64,200,000	Nov 26 04:58 PM
Casdin Partners Master Fund, L	Director	Nov 20 '25	Buy	1.30	450,000	586,260	64,050,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 19 '25	Buy	1.28	350,000	448,910	63,600,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 18 '25	Buy	1.23	275,000	339,405	63,250,000	Nov 20 07:45 PM
Casdin Partners Master Fund, L	Director	Nov 13 '25	Buy	1.20	450,000	541,395	62,500,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 14 '25	Buy	1.24	250,000	309,800	62,750,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 17 '25	Buy	1.22	225,000	275,580	62,975,000	Nov 17 06:58 PM
Casdin Partners Master Fund, L	Director	Nov 12 '25	Buy	1.19	375,000	445,838	62,050,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 11 '25	Buy	1.20	300,000	358,800	61,675,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 10 '25	Buy	1.17	275,000	321,915	61,375,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Nov 07 '25	Buy	1.12	225,000	252,765	61,100,000	Nov 12 07:46 PM
Casdin Partners Master Fund, L	Director	Sep 09 '25	Buy	1.29	100,000	128,920	60,875,000	Sep 11 09:03 PM
Casdin Partners Master Fund, L	Director	Sep 04 '25	Buy	1.28	250,000	319,350	60,775,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Sep 03 '25	Buy	1.27	250,000	316,400	60,525,000	Sep 05 07:08 PM
Casdin Partners Master Fund, L	Director	Aug 22 '25	Buy	1.26	200,000	252,680	59,950,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 25 '25	Buy	1.24	200,000	248,180	60,150,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 26 '25	Buy	1.26	125,000	157,938	60,275,000	Aug 26 08:46 PM
Casdin Partners Master Fund, L	Director	Aug 15 '25	Buy	1.22	150,000	183,210	59,750,000	Aug 15 09:18 PM
Casdin Partners Master Fund, L	Director	Aug 14 '25	Buy	1.21	133,220	161,543	59,600,000	Aug 15 09:18 PM
Casdin Partners Master Fund, L	Director	Aug 13 '25	Buy	1.31	75,000	98,280	59,466,780	Aug 15 09:18 PM
Kim Hanjoon Alex	Chief Financial Officer	May 23 '25	Sale	0.94	1,428	1,344	930,286	May 28 05:54 PM
Mackay Sean	SVP & Chief Business Officer	May 23 '25	Sale	0.94	13,217	12,437	843,076	May 28 05:52 PM
Egholm Michael	President & CEO	May 23 '25	Sale	0.94	5,473	5,150	2,741,191	May 28 05:44 PM
Kim Hanjoon Alex	Chief Financial Officer	May 22 '25	Sale	1.00	1,355	1,358	931,714	May 27 08:33 PM
Egholm Michael	President & CEO	May 22 '25	Sale	1.00	5,116	5,126	2,746,664	May 27 08:28 PM
Mackay Sean	SVP & Chief Business Officer	May 21 '25	Sale	1.03	12,838	13,223	868,829	May 23 06:13 PM
Mackay Sean	SVP & Chief Business Officer	May 22 '25	Sale	1.00	12,536	12,561	856,293	May 23 06:13 PM
Mackay Sean	Officer	May 23 '25	Proposed Sale	0.94	13,217	12,441		May 23 04:19 PM
Kim Hanjoon Alex	Officer	May 23 '25	Proposed Sale	0.94	1,428	1,344		May 23 04:18 PM
Egholm Michael	Officer	May 23 '25	Proposed Sale	0.94	5,473	5,152		May 23 04:09 PM
Egholm Michael	President & CEO	May 21 '25	Sale	1.03	4,719	4,861	2,751,780	May 22 08:03 PM
Kim Hanjoon Alex	Chief Financial Officer	May 21 '25	Sale	1.03	1,407	1,449	933,069	May 22 08:01 PM
Egholm Michael	Officer	May 22 '25	Proposed Sale	1.00	5,116	5,126		May 22 04:20 PM
Mackay Sean	Officer	May 22 '25	Proposed Sale	1.00	12,536	12,560		May 22 04:13 PM
Kim Hanjoon Alex	Officer	May 22 '25	Proposed Sale	1.00	1,355	1,358		May 22 04:07 PM
Kim Hanjoon Alex	Officer	May 21 '25	Proposed Sale	1.03	1,407	1,451		May 21 04:22 PM
Mackay Sean	Officer	May 21 '25	Proposed Sale	1.03	12,838	13,240		May 21 04:16 PM
Egholm Michael	Officer	May 21 '25	Proposed Sale	1.03	4,719	4,867		May 21 04:13 PM
Egholm Michael	President & CEO	Apr 04 '25	Option Exercise	0.00	196,512	0	2,832,518	Apr 08 04:04 PM
Kim Hanjoon Alex	Chief Financial Officer	Apr 04 '25	Option Exercise	0.00	70,183	0	962,281	Apr 08 04:03 PM
Casdin Partners Master Fund, L	Director	Feb 28 '25	Buy	1.06	4,820,959	5,134,321	58,846,780	Mar 04 08:19 PM

XGN

Exagen Inc

LAB

Standard BioTools Inc

Upgrade your FINVIZ experience